Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 23 entries
Sorted by: Best Match Show Resources per page
High precision canonical Monte Carlo determination of the growth constant of square lattice trees.

Physical review. E, Statistical, nonlinear, and soft matter physics

Janse van Rensburg EJ, Rechnitzer A.
PMID: 12689141
Phys Rev E Stat Nonlin Soft Matter Phys. 2003 Mar;67(3):036116. doi: 10.1103/PhysRevE.67.036116. Epub 2003 Mar 24.

The number of lattice bond trees in the square lattice (counted modulo translations), t(n), is a basic quantity in lattice statistical mechanical models of branched polymers. This number is believed to have asymptotic behavior given by t(n) approximately Alambda(n)n(-theta),...

Cite
Janse van Rensburg EJ, Rechnitzer A. High precision canonical Monte Carlo determination of the growth constant of square lattice trees. Phys Rev E Stat Nonlin Soft Matter Phys. 2003;67(3):036116doi: 10.1103/PhysRevE.67.036116.
Janse van Rensburg, E. J., & Rechnitzer, A. (2003). High precision canonical Monte Carlo determination of the growth constant of square lattice trees. Physical review. E, Statistical, nonlinear, and soft matter physics, 67(3), 036116. https://doi.org/10.1103/PhysRevE.67.036116
Janse van Rensburg, E J, and Rechnitzer, A. "High precision canonical Monte Carlo determination of the growth constant of square lattice trees." Physical review. E, Statistical, nonlinear, and soft matter physics vol. 67,3 (2003): 036116. doi: https://doi.org/10.1103/PhysRevE.67.036116
Janse van Rensburg EJ, Rechnitzer A. High precision canonical Monte Carlo determination of the growth constant of square lattice trees. Phys Rev E Stat Nonlin Soft Matter Phys. 2003 Mar;67(3):036116. doi: 10.1103/PhysRevE.67.036116. Epub 2003 Mar 24. PMID: 12689141.
Copy Download .nbib Format: NLM
A novel DICER1 mutation identified in a female with ovarian Sertoli-Leydig cell tumor and multinodular goiter: a case report.

Journal of medical case reports

Rossing M, Gerdes AM, Juul A, Rechnitzer C, Rudnicki M, Nielsen FC, Vo Hansen T.
PMID: 24708902
J Med Case Rep. 2014 Apr 03;8:112. doi: 10.1186/1752-1947-8-112.

INTRODUCTION: Germ-line mutations in the micro-ribonucleic acid processing gene DICER1 have been shown to predispose to a subset of benign tumors susceptible to malignant transformation, including ovarian Sertoli-Leydig cell tumor, nontoxic multinodular goiter, multilocular cystic nephroma and pleuropulmonary blastoma,...

Cite
Rossing M, Gerdes AM, Juul A, et al. A novel DICER1 mutation identified in a female with ovarian Sertoli-Leydig cell tumor and multinodular goiter: a case report. J Med Case Rep. 2014;8:112doi: 10.1186/1752-1947-8-112.
Rossing, M., Gerdes, A. M., Juul, A., Rechnitzer, C., Rudnicki, M., Nielsen, F. C., & Vo Hansen, T. (2014). A novel DICER1 mutation identified in a female with ovarian Sertoli-Leydig cell tumor and multinodular goiter: a case report. Journal of medical case reports, 8112. https://doi.org/10.1186/1752-1947-8-112
Rossing, Maria, et al. "A novel DICER1 mutation identified in a female with ovarian Sertoli-Leydig cell tumor and multinodular goiter: a case report." Journal of medical case reports vol. 8 (2014): 112. doi: https://doi.org/10.1186/1752-1947-8-112
Rossing M, Gerdes AM, Juul A, Rechnitzer C, Rudnicki M, Nielsen FC, Vo Hansen T. A novel DICER1 mutation identified in a female with ovarian Sertoli-Leydig cell tumor and multinodular goiter: a case report. J Med Case Rep. 2014 Apr 03;8:112. doi: 10.1186/1752-1947-8-112. PMID: 24708902; PMCID: PMC4234993.
Copy Download .nbib Format: NLM
Somatic Disease in Survivors of Childhood Malignant Bone Tumors in the Nordic Countries.

Cancers

Pedersen C, Rechnitzer C, Andersen EAW, Kenborg L, Norsker FN, Bautz A, Baad-Hansen T, Tryggvadottir L, Madanat-Harjuoja LM, Holmqvist AS, Hjorth L, Hasle H, Winther JF, On Behalf Of The ALiCCS Study Group.
PMID: 34572734
Cancers (Basel). 2021 Sep 07;13(18). doi: 10.3390/cancers13184505.

Survivors of malignant bone tumors in childhood are at risk of long-term adverse health effects. We comprehensively reviewed cases of somatic diseases that required a hospital contact in survivors of osteosarcoma and Ewing sarcoma. In a population-based cohort study,...

Cite
Pedersen C, Rechnitzer C, Andersen EAW, et al. Somatic Disease in Survivors of Childhood Malignant Bone Tumors in the Nordic Countries. Cancers (Basel). 2021;13(18)doi: 10.3390/cancers13184505.
Pedersen, C., Rechnitzer, C., Andersen, E. A. W., Kenborg, L., Norsker, F. N., Bautz, A., Baad-Hansen, T., Tryggvadottir, L., Madanat-Harjuoja, L. M., Holmqvist, A. S., Hjorth, L., Hasle, H., Winther, J. F., & On Behalf Of The ALiCCS Study Group. (2021). Somatic Disease in Survivors of Childhood Malignant Bone Tumors in the Nordic Countries. Cancers, 13(18), . https://doi.org/10.3390/cancers13184505
Pedersen, Camilla, et al. "Somatic Disease in Survivors of Childhood Malignant Bone Tumors in the Nordic Countries." Cancers vol. 13,18 (2021). doi: https://doi.org/10.3390/cancers13184505
Pedersen C, Rechnitzer C, Andersen EAW, Kenborg L, Norsker FN, Bautz A, Baad-Hansen T, Tryggvadottir L, Madanat-Harjuoja LM, Holmqvist AS, Hjorth L, Hasle H, Winther JF, On Behalf Of The ALiCCS Study Group. Somatic Disease in Survivors of Childhood Malignant Bone Tumors in the Nordic Countries. Cancers (Basel). 2021 Sep 07;13(18). doi: 10.3390/cancers13184505. PMID: 34572734; PMCID: PMC8467516.
Copy Download .nbib Format: NLM
Association of candidate pharmacogenetic markers with platinum-induced ototoxicity: PanCareLIFE dataset.

Data in brief

Langer T, Clemens E, Broer L, Maier L, Uitterlinden AG, de Vries ACH, van Grotel M, Pluijm SFM, Binder H, Mayer B, von dem Knesebeck A, Byrne J, van Dulmen-den Broeder E, Crocco M, Grabow D, Kaatsch P, Kaiser M, Spix C, Kenborg L, Winther JF, Rechnitzer C, Hasle H, Kepak T, van der Kooi AF, Kremer LC, Kruseova J, Bielack S, Sorg B, Hecker-Nolting S, Kuehni CE, Ansari M, Kompis M, van der Pal HJ, Parfitt R, Deuster D, Matulat P, Tillmanns A, Tissing WJE, Beck JD, Elsner S, Am Zehnhoff-Dinnesen A, van den Heuvel-Eibrink MM, Zolk O.
PMID: 32939381
Data Brief. 2020 Aug 24;32:106227. doi: 10.1016/j.dib.2020.106227. eCollection 2020 Oct.

Genetic association studies suggest a genetic predisposition for cisplatin-induced ototoxicity. Among other candidate genes, thiopurine methyltransferase (

Cite
Langer T, Clemens E, Broer L, et al. Association of candidate pharmacogenetic markers with platinum-induced ototoxicity: PanCareLIFE dataset. Data Brief. 2020;32:106227doi: 10.1016/j.dib.2020.106227.
Langer, T., Clemens, E., Broer, L., Maier, L., Uitterlinden, A. G., de Vries, A. C. H., van Grotel, M., Pluijm, S. F. M., Binder, H., Mayer, B., von dem Knesebeck, A., Byrne, J., van Dulmen-den Broeder, E., Crocco, M., Grabow, D., Kaatsch, P., Kaiser, M., Spix, C., Kenborg, L., Winther, J. F., Rechnitzer, C., Hasle, H., Kepak, T., van der Kooi, A. F., Kremer, L. C., Kruseova, J., Bielack, S., Sorg, B., Hecker-Nolting, S., Kuehni, C. E., Ansari, M., Kompis, M., van der Pal, H. J., Parfitt, R., Deuster, D., Matulat, P., Tillmanns, A., Tissing, W. J. E., Beck, J. D., Elsner, S., Am Zehnhoff-Dinnesen, A., van den Heuvel-Eibrink, M. M., Zolk, O. (2020). Association of candidate pharmacogenetic markers with platinum-induced ototoxicity: PanCareLIFE dataset. Data in brief, 32106227. https://doi.org/10.1016/j.dib.2020.106227
Langer, Thorsten, et al. "Association of candidate pharmacogenetic markers with platinum-induced ototoxicity: PanCareLIFE dataset." Data in brief vol. 32 (2020): 106227. doi: https://doi.org/10.1016/j.dib.2020.106227
Langer T, Clemens E, Broer L, Maier L, Uitterlinden AG, de Vries ACH, van Grotel M, Pluijm SFM, Binder H, Mayer B, von dem Knesebeck A, Byrne J, van Dulmen-den Broeder E, Crocco M, Grabow D, Kaatsch P, Kaiser M, Spix C, Kenborg L, Winther JF, Rechnitzer C, Hasle H, Kepak T, van der Kooi AF, Kremer LC, Kruseova J, Bielack S, Sorg B, Hecker-Nolting S, Kuehni CE, Ansari M, Kompis M, van der Pal HJ, Parfitt R, Deuster D, Matulat P, Tillmanns A, Tissing WJE, Beck JD, Elsner S, Am Zehnhoff-Dinnesen A, van den Heuvel-Eibrink MM, Zolk O. Association of candidate pharmacogenetic markers with platinum-induced ototoxicity: PanCareLIFE dataset. Data Brief. 2020 Aug 24;32:106227. doi: 10.1016/j.dib.2020.106227. eCollection 2020 Oct. PMID: 32939381; PMCID: PMC7477761.
Copy Download .nbib Format: NLM
Background sensitivity to chemotherapy-induced nausea and vomiting and response to antiemetics in paediatric patients: a genetic association study.

Pharmacogenetics and genomics

Eliasen A, Kornholt J, Mathiasen R, Wadt K, Stoltze U, Brok J, Rechnitzer C, Schmiegelow K, Dalhoff K.
PMID: 34750329
Pharmacogenet Genomics. 2022 Feb 01;32(2):72-78. doi: 10.1097/FPC.0000000000000460.

Chemotherapy-induced nausea and vomiting (CINV) remains a common adverse effect for children with cancer. In children, chemotherapy emetogenicity and patient factors such as susceptibility to motion sickness and age group determine a patient's risk of CINV. Besides known risk...

Cite
Eliasen A, Kornholt J, Mathiasen R, et al. Background sensitivity to chemotherapy-induced nausea and vomiting and response to antiemetics in paediatric patients: a genetic association study. Pharmacogenet Genomics. 2022;32(2):72-78doi: 10.1097/FPC.0000000000000460.
Eliasen, A., Kornholt, J., Mathiasen, R., Wadt, K., Stoltze, U., Brok, J., Rechnitzer, C., Schmiegelow, K., & Dalhoff, K. (2022). Background sensitivity to chemotherapy-induced nausea and vomiting and response to antiemetics in paediatric patients: a genetic association study. Pharmacogenetics and genomics, 32(2), 72-78. https://doi.org/10.1097/FPC.0000000000000460
Eliasen, Astrid, et al. "Background sensitivity to chemotherapy-induced nausea and vomiting and response to antiemetics in paediatric patients: a genetic association study." Pharmacogenetics and genomics vol. 32,2 (2022): 72-78. doi: https://doi.org/10.1097/FPC.0000000000000460
Eliasen A, Kornholt J, Mathiasen R, Wadt K, Stoltze U, Brok J, Rechnitzer C, Schmiegelow K, Dalhoff K. Background sensitivity to chemotherapy-induced nausea and vomiting and response to antiemetics in paediatric patients: a genetic association study. Pharmacogenet Genomics. 2022 Feb 01;32(2):72-78. doi: 10.1097/FPC.0000000000000460. PMID: 34750329.
Copy Download .nbib Format: NLM
Clinical Predictors of Mortality and Critical Illness in Patients with COVID-19 Pneumonia.

Metabolites

Basheer M, Saad E, Hagai R, Assy N.
PMID: 34677394
Metabolites. 2021 Oct 02;11(10). doi: 10.3390/metabo11100679.

Early identification of patients with COVID-19 who will develop severe or critical disease symptoms is important for delivering proper and early treatment. We analyzed demographic, clinical, immunological, hematological, biochemical and radiographic findings that may be of utility to clinicians...

Cite
Basheer M, Saad E, Hagai R, et al. Clinical Predictors of Mortality and Critical Illness in Patients with COVID-19 Pneumonia. Metabolites. 2021;11(10)doi: 10.3390/metabo11100679.
Basheer, M., Saad, E., Hagai, R., & Assy, N. (2021). Clinical Predictors of Mortality and Critical Illness in Patients with COVID-19 Pneumonia. Metabolites, 11(10), . https://doi.org/10.3390/metabo11100679
Basheer, Maamoun, et al. "Clinical Predictors of Mortality and Critical Illness in Patients with COVID-19 Pneumonia." Metabolites vol. 11,10 (2021). doi: https://doi.org/10.3390/metabo11100679
Basheer M, Saad E, Hagai R, Assy N. Clinical Predictors of Mortality and Critical Illness in Patients with COVID-19 Pneumonia. Metabolites. 2021 Oct 02;11(10). doi: 10.3390/metabo11100679. PMID: 34677394; PMCID: PMC8540216.
Copy Download .nbib Format: NLM
Genetic Determinants of Ototoxicity During and After Childhood Cancer Treatment: Protocol for the PanCareLIFE Study.

JMIR research protocols

Clemens E, Meijer AJ, Broer L, Langer T, van der Kooi AL, Uitterlinden AG, de Vries A, Kuehni CE, Garrè ML, Kepak T, Kruseova J, Winther JF, Kremer LC, van Dulmen-den Broeder E, Tissing WJ, Rechnitzer C, Kenborg L, Hasle H, Grabow D, Parfitt R, Binder H, Carleton BC, Byrne J, Kaatsch P, Am Zehnhoff-Dinnesen A, Zolk O, van den Heuvel-Eibrink MM.
PMID: 30888333
JMIR Res Protoc. 2019 Mar 19;8(3):e11868. doi: 10.2196/11868.

BACKGROUND: Survival rates after childhood cancer now reach nearly 80% in developed countries. However, treatments that lead to survival and cure can cause serious adverse effects with lifelong negative impacts on survivor quality of life. Hearing impairment is a...

Cite
Clemens E, Meijer AJ, Broer L, et al. Genetic Determinants of Ototoxicity During and After Childhood Cancer Treatment: Protocol for the PanCareLIFE Study. JMIR Res Protoc. 2019;8(3):e11868doi: 10.2196/11868.
Clemens, E., Meijer, A. J., Broer, L., Langer, T., van der Kooi, A. L., Uitterlinden, A. G., de Vries, A., Kuehni, C. E., Garrè, M. L., Kepak, T., Kruseova, J., Winther, J. F., Kremer, L. C., van Dulmen-den Broeder, E., Tissing, W. J., Rechnitzer, C., Kenborg, L., Hasle, H., Grabow, D., Parfitt, R., Binder, H., Carleton, B. C., Byrne, J., Kaatsch, P., Am Zehnhoff-Dinnesen, A., Zolk, O., & van den Heuvel-Eibrink, M. M. (2019). Genetic Determinants of Ototoxicity During and After Childhood Cancer Treatment: Protocol for the PanCareLIFE Study. JMIR research protocols, 8(3), e11868. https://doi.org/10.2196/11868
Clemens, Eva, et al. "Genetic Determinants of Ototoxicity During and After Childhood Cancer Treatment: Protocol for the PanCareLIFE Study." JMIR research protocols vol. 8,3 (2019): e11868. doi: https://doi.org/10.2196/11868
Clemens E, Meijer AJ, Broer L, Langer T, van der Kooi AL, Uitterlinden AG, de Vries A, Kuehni CE, Garrè ML, Kepak T, Kruseova J, Winther JF, Kremer LC, van Dulmen-den Broeder E, Tissing WJ, Rechnitzer C, Kenborg L, Hasle H, Grabow D, Parfitt R, Binder H, Carleton BC, Byrne J, Kaatsch P, Am Zehnhoff-Dinnesen A, Zolk O, van den Heuvel-Eibrink MM. Genetic Determinants of Ototoxicity During and After Childhood Cancer Treatment: Protocol for the PanCareLIFE Study. JMIR Res Protoc. 2019 Mar 19;8(3):e11868. doi: 10.2196/11868. PMID: 30888333; PMCID: PMC6444213.
Copy Download .nbib Format: NLM
Antidepressant Use in Siblings of Children With Cancer: A Danish Population-Based Cohort Study.

JNCI cancer spectrum

Lund LW, Winther JF, Cederkvist L, Rechnitzer C, Dalton SO, Appel CW, Schmiegelow K, Johansen C.
PMID: 33134828
JNCI Cancer Spectr. 2020 Jun 13;4(5):pkaa046. doi: 10.1093/jncics/pkaa046. eCollection 2020 Oct.

Siblings of children with cancer experience severe stress early in life. Most studies of mental health problems in these siblings are limited by being small, cross-sectional, or self-reporting. In a population-based cohort study, we investigated the risk for antidepressant...

Cite
Lund LW, Winther JF, Cederkvist L, et al. Antidepressant Use in Siblings of Children With Cancer: A Danish Population-Based Cohort Study. JNCI Cancer Spectr. 2020;4(5):pkaa046doi: 10.1093/jncics/pkaa046.
Lund, L. W., Winther, J. F., Cederkvist, L., Rechnitzer, C., Dalton, S. O., Appel, C. W., Schmiegelow, K., & Johansen, C. (2020). Antidepressant Use in Siblings of Children With Cancer: A Danish Population-Based Cohort Study. JNCI cancer spectrum, 4(5), pkaa046. https://doi.org/10.1093/jncics/pkaa046
Lund, Lasse Wegener, et al. "Antidepressant Use in Siblings of Children With Cancer: A Danish Population-Based Cohort Study." JNCI cancer spectrum vol. 4,5 (2020): pkaa046. doi: https://doi.org/10.1093/jncics/pkaa046
Lund LW, Winther JF, Cederkvist L, Rechnitzer C, Dalton SO, Appel CW, Schmiegelow K, Johansen C. Antidepressant Use in Siblings of Children With Cancer: A Danish Population-Based Cohort Study. JNCI Cancer Spectr. 2020 Jun 13;4(5):pkaa046. doi: 10.1093/jncics/pkaa046. eCollection 2020 Oct. PMID: 33134828; PMCID: PMC7583159.
Copy Download .nbib Format: NLM
Background sensitivity to chemotherapy-induced nausea and vomiting and response to antiemetics in paediatric patients: a genetic association study.

Pharmacogenetics and genomics

Eliasen A, Kornholt J, Mathiasen R, Wadt K, Stoltze U, Brok J, Rechnitzer C, Schmiegelow K, Dalhoff K.
PMID: 34750329
Pharmacogenet Genomics. 2021 Nov 08; doi: 10.1097/FPC.0000000000000460. Epub 2021 Nov 08.

Chemotherapy-induced nausea and vomiting (CINV) remains a common adverse effect for children with cancer. In children, chemotherapy emetogenicity and patient factors such as susceptibility to motion sickness and age group determine a patient's risk of CINV. Besides known risk...

Cite
Eliasen A, Kornholt J, Mathiasen R, et al. Background sensitivity to chemotherapy-induced nausea and vomiting and response to antiemetics in paediatric patients: a genetic association study. Pharmacogenet Genomics. 2021;doi: 10.1097/FPC.0000000000000460.
Eliasen, A., Kornholt, J., Mathiasen, R., Wadt, K., Stoltze, U., Brok, J., Rechnitzer, C., Schmiegelow, K., & Dalhoff, K. (2021). Background sensitivity to chemotherapy-induced nausea and vomiting and response to antiemetics in paediatric patients: a genetic association study. Pharmacogenetics and genomics, . https://doi.org/10.1097/FPC.0000000000000460
Eliasen, Astrid, et al. "Background sensitivity to chemotherapy-induced nausea and vomiting and response to antiemetics in paediatric patients: a genetic association study." Pharmacogenetics and genomics vol. (2021). doi: https://doi.org/10.1097/FPC.0000000000000460
Eliasen A, Kornholt J, Mathiasen R, Wadt K, Stoltze U, Brok J, Rechnitzer C, Schmiegelow K, Dalhoff K. Background sensitivity to chemotherapy-induced nausea and vomiting and response to antiemetics in paediatric patients: a genetic association study. Pharmacogenet Genomics. 2021 Nov 08; doi: 10.1097/FPC.0000000000000460. Epub 2021 Nov 08. PMID: 34750329.
Copy Download .nbib Format: NLM
Background sensitivity to chemotherapy-induced nausea and vomiting and response to antiemetics in paediatric patients: a genetic association study.

Pharmacogenetics and genomics

Eliasen A, Kornholt J, Mathiasen R, Wadt K, Stoltze U, Brok J, Rechnitzer C, Schmiegelow K, Dalhoff K.
PMID: 34750329
Pharmacogenet Genomics. 2022 Feb 01;32(2):72-78. doi: 10.1097/FPC.0000000000000460.

Chemotherapy-induced nausea and vomiting (CINV) remains a common adverse effect for children with cancer. In children, chemotherapy emetogenicity and patient factors such as susceptibility to motion sickness and age group determine a patient's risk of CINV. Besides known risk...

Cite
Eliasen A, Kornholt J, Mathiasen R, et al. Background sensitivity to chemotherapy-induced nausea and vomiting and response to antiemetics in paediatric patients: a genetic association study. Pharmacogenet Genomics. 2022;32(2):72-78doi: 10.1097/FPC.0000000000000460.
Eliasen, A., Kornholt, J., Mathiasen, R., Wadt, K., Stoltze, U., Brok, J., Rechnitzer, C., Schmiegelow, K., & Dalhoff, K. (2022). Background sensitivity to chemotherapy-induced nausea and vomiting and response to antiemetics in paediatric patients: a genetic association study. Pharmacogenetics and genomics, 32(2), 72-78. https://doi.org/10.1097/FPC.0000000000000460
Eliasen, Astrid, et al. "Background sensitivity to chemotherapy-induced nausea and vomiting and response to antiemetics in paediatric patients: a genetic association study." Pharmacogenetics and genomics vol. 32,2 (2022): 72-78. doi: https://doi.org/10.1097/FPC.0000000000000460
Eliasen A, Kornholt J, Mathiasen R, Wadt K, Stoltze U, Brok J, Rechnitzer C, Schmiegelow K, Dalhoff K. Background sensitivity to chemotherapy-induced nausea and vomiting and response to antiemetics in paediatric patients: a genetic association study. Pharmacogenet Genomics. 2022 Feb 01;32(2):72-78. doi: 10.1097/FPC.0000000000000460. PMID: 34750329.
Copy Download .nbib Format: NLM
Background sensitivity to chemotherapy-induced nausea and vomiting and response to antiemetics in paediatric patients: a genetic association study.

Pharmacogenetics and genomics

Eliasen A, Kornholt J, Mathiasen R, Wadt K, Stoltze U, Brok J, Rechnitzer C, Schmiegelow K, Dalhoff K.
PMID: 34750329
Pharmacogenet Genomics. 2022 Feb 01;32(2):72-78. doi: 10.1097/FPC.0000000000000460.

Chemotherapy-induced nausea and vomiting (CINV) remains a common adverse effect for children with cancer. In children, chemotherapy emetogenicity and patient factors such as susceptibility to motion sickness and age group determine a patient's risk of CINV. Besides known risk...

Cite
Eliasen A, Kornholt J, Mathiasen R, et al. Background sensitivity to chemotherapy-induced nausea and vomiting and response to antiemetics in paediatric patients: a genetic association study. Pharmacogenet Genomics. 2022;32(2):72-78doi: 10.1097/FPC.0000000000000460.
Eliasen, A., Kornholt, J., Mathiasen, R., Wadt, K., Stoltze, U., Brok, J., Rechnitzer, C., Schmiegelow, K., & Dalhoff, K. (2022). Background sensitivity to chemotherapy-induced nausea and vomiting and response to antiemetics in paediatric patients: a genetic association study. Pharmacogenetics and genomics, 32(2), 72-78. https://doi.org/10.1097/FPC.0000000000000460
Eliasen, Astrid, et al. "Background sensitivity to chemotherapy-induced nausea and vomiting and response to antiemetics in paediatric patients: a genetic association study." Pharmacogenetics and genomics vol. 32,2 (2022): 72-78. doi: https://doi.org/10.1097/FPC.0000000000000460
Eliasen A, Kornholt J, Mathiasen R, Wadt K, Stoltze U, Brok J, Rechnitzer C, Schmiegelow K, Dalhoff K. Background sensitivity to chemotherapy-induced nausea and vomiting and response to antiemetics in paediatric patients: a genetic association study. Pharmacogenet Genomics. 2022 Feb 01;32(2):72-78. doi: 10.1097/FPC.0000000000000460. PMID: 34750329.
Copy Download .nbib Format: NLM
Vascularized fibula grafts for reconstruction of bone defects after resection of bone sarcomas.

Sarcoma

Petersen MM, Hovgaard D, Elberg JJ, Rechnitzer C, Daugaard S, Muhic A.
PMID: 20490263
Sarcoma. 2010;2010:524721. doi: 10.1155/2010/524721. Epub 2010 May 13.

We evaluated the results of limb-sparing surgery and reconstruction of bone defects with vascularized fibula grafts in 8 consecutive patients (mean age at operation 13.6 years (range 4.1-24.2 years), female/male = 6/2) with bone sarcomas (BS) (osteosarcoma/Ewing's sarcoma/chondrosarcoma= 4/3/1)...

Cite
Petersen MM, Hovgaard D, Elberg JJ, et al. Vascularized fibula grafts for reconstruction of bone defects after resection of bone sarcomas. Sarcoma. 2010;2010:524721doi: 10.1155/2010/524721.
Petersen, M. M., Hovgaard, D., Elberg, J. J., Rechnitzer, C., Daugaard, S., & Muhic, A. (2010). Vascularized fibula grafts for reconstruction of bone defects after resection of bone sarcomas. Sarcoma, 2010524721. https://doi.org/10.1155/2010/524721
Petersen, Michael Mørk, et al. "Vascularized fibula grafts for reconstruction of bone defects after resection of bone sarcomas." Sarcoma vol. 2010 (2010): 524721. doi: https://doi.org/10.1155/2010/524721
Petersen MM, Hovgaard D, Elberg JJ, Rechnitzer C, Daugaard S, Muhic A. Vascularized fibula grafts for reconstruction of bone defects after resection of bone sarcomas. Sarcoma. 2010;2010:524721. doi: 10.1155/2010/524721. Epub 2010 May 13. PMID: 20490263; PMCID: PMC2871185.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 23 entries